Year-end earn­ings show tur­bu­lent times for Hal Bar­ron's Glax­o­SmithK­line turn­around

Hal Bar­ron and Em­ma Walm­s­ley’s big Glax­o­SmithK­line piv­ot may ul­ti­mate­ly prove suc­cess­ful, de­liv­er­ing block­busters in can­cer, au­to-im­mune con­di­tions and in­fec­tious dis­ease. But the path …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER